Juho Jalkanen

Company: Faron Pharmaceuticals

Job title: Chief Development Officer

Seminars:

Modifying Immunosuppressive Macrophages To Immune Stimulatory To Enhance Anti- Tumor Immune Activity 2:00 pm

Exploring the use of CLEVER-1 antagonist antibody, as a macrophage checkpoint inhibitor to reverse PD-1 inhibitor resistance Insights into dose escalation studies and demonstrating proof of concept in tumor specific expansion cohortsRead more

day: Clinical Development – Day 2 pm